Welcome to our dedicated page for TRINITY BIOTECH PLC SEC filings (Ticker: TRIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trinity Biotech plc SEC filings document foreign-issuer reports furnished on Form 6-K for its diagnostics, diabetes management, and health technology operations. The filings record announcements tied to Premier Hb9210 diabetes testing, CGM+ biosensor development, EpiCapture prostate cancer diagnostics, North America commercial operations, trading updates, and the Comprehensive Transformation Plan.
The company’s filings also disclose ADS and ordinary-share capital matters, including a standby equity purchase agreement; credit-agreement waivers and covenant deferrals; Nasdaq listing-compliance notices for the ADSs; and incorporation by reference into Form S-8 registration statements. These records describe the formal reporting framework for Trinity Biotech as a foreign private issuer using Form 20-F reporting status.
Trinity Biotech plc has entered into a Standby Equity Purchase Agreement with YA II PN, Ltd., giving the company the right, but not the obligation, to sell up to $25 million of American Depositary Shares (ADSs), each representing 20 class A ordinary shares.
ADSs sold under the agreement will be priced at 95% of the ADS volume‑weighted average price (VWAP) for a one‑day pricing period or 97% of the lowest VWAP over a three‑day period. The facility runs until the earlier of February 24, 2029 or when the full $25 million is purchased, is subject to an effective resale registration statement, and includes a 4.99% beneficial ownership cap for the investor. Trinity Biotech will pay a $35,000 structuring fee and a commitment fee satisfied by issuing 175,537 ADSs.
Trinity Biotech plc received a Nasdaq notice that it no longer meets the Nasdaq Global Select Market requirement that listed securities maintain a minimum market value of publicly held shares of $15,000,000 based on the last 30 consecutive business days.
The company’s ADSs remain listed and trading on the Nasdaq Global Select Market under the symbol TRIB, with no immediate effect from the notice. Trinity Biotech has 180 calendar days, until August 18, 2026, to regain compliance by having its market value of publicly held shares exceed $15,000,000 for at least 10 consecutive business days, or it may seek transfer to The Nasdaq Capital Market if it meets those listing standards.
If it fails to regain compliance or transfer by that date, Nasdaq may move to delist the ADSs, a decision the company could appeal to a hearings panel, though success is not assured.
Trinity Biotech plc filed a prospectus supplement covering the resale by selling shareholders of up to 1,117,818,000 Ordinary Shares, represented by up to 55,890,900 ADSs. The supplement incorporates a recent Form 6-K reporting that Nasdaq notified the company its ADSs no longer meet the minimum bid price requirement of US $1.00 per share after trading below that level for 30 consecutive business days. Trinity Biotech has 180 calendar days, until August 10, 2026, to regain compliance while its ADSs, which last traded at $0.77 on February 13, 2026, remain listed on the Nasdaq Global Select Market.
Trinity Biotech plc received a notice from Nasdaq that its American Depositary Shares are not in compliance with the Nasdaq Global Select Market’s minimum bid price requirement of $1.00 per share, after trading below this level for 30 consecutive business days.
The company has 180 calendar days, until August 10, 2026, to regain compliance by having its closing bid price at or above $1.00 for at least ten consecutive business days. The notice has no immediate effect on the listing, and the ADSs continue to trade on the Nasdaq Global Select Market under the symbol TRIB.
If compliance is not regained within this period, the company may qualify for additional time on The Nasdaq Capital Market if it meets the minimum value of publicly held shares requirement of $15,000,000 and other initial listing standards. Management is monitoring the share price and evaluating options to maintain the listing.
Trinity Biotech plc filed a Form 6-K highlighting two operational milestones. The company’s Premier Hb9210™ HbA1c analyser, with its next‑generation Buffer A Plus column system, achieved IFCC Gold Classification for 2026, making it the only HbA1c system worldwide to receive this top‑tier certification.
The filing also notes full regulatory approval to begin upstream manufacturing of the Uni‑Gold™ HIV rapid test under an offshored and outsourced model. Management describes this as the final major regulatory milestone in its transformation plan and expects the new model to support gross margin expansion, better working capital efficiency, and improved long‑term scalability.
Perceptive Advisors and related funds filed Amendment No. 7 to update their ownership in Trinity Biotech plc. The reporting persons disclose beneficial ownership of 1,463,058,248 Class A Ordinary Shares, representing 9.9% of the class based on 374,206,640 Ordinary Shares outstanding and assuming exercise and conversion of their instruments to the extent permitted by a Beneficial Ownership Cap.
The position is held through Perceptive Credit Holdings II, L.P. and Perceptive Credit Holdings III, L.P. via a mix of warrants, a Convertible Note, and milestone and contingent payment obligations, including 65,000,000 Ordinary Shares issuable upon warrant exercise and 1,165,048,540 Ordinary Shares represented by 58,252,427 ADSs issuable upon conversion of the Convertible Note at a floor price of $1.03. Similar conversion mechanics apply to the milestone and contingent obligations. All of these instruments are contractually restricted so that exercises or conversions cannot raise the reporting group’s beneficial ownership above the 9.9% Beneficial Ownership Cap, and the reporting persons expressly disclaim beneficial ownership above that level.
Trinity Biotech plc is registering up to 55,890,900 American Depositary Shares (ADSs), representing 1,117,818,000 Ordinary Shares, for resale by Perceptive-affiliated selling shareholders. These ADSs are issuable upon conversion of up to $60 million of a convertible note and related payment obligations under conversion agreements with Perceptive funds.
The ADS conversion price is 97% of the volume-weighted average price, subject to a $1.03 floor and a 9.9% beneficial ownership cap. The company will not receive cash from the resale of ADSs and will not receive cash from conversions, but each conversion reduces outstanding debt under the credit agreement and conversion rights. Ordinary Shares outstanding before the sale were 374,206,640, which means full conversion could significantly dilute existing holders, and the company already carries substantial indebtedness, including a term loan due in January 2027.
Trinity Biotech plc has filed to register the resale of up to 55,890,900 American Depositary Shares (ADSs), representing 1,117,818,000 ordinary shares, issuable on conversion of debt owed to Perceptive funds. The ADSs may be issued upon conversion of up to $60,000,000 of a senior convertible note and $12,500,000 of other payment obligations, at a price based on 97% of the ADS volume-weighted average price, subject to a $1.03 floor and a 9.9% beneficial ownership cap.
Trinity will not receive cash from any resale of ADSs by the selling shareholders, but any conversions would reduce outstanding debt under its credit agreement. As of December 31, 2025, the company reported total indebtedness of about $134.58 million, including a term loan of $100.82 million due in January 2027. The company warns that conversions and subsequent sales could cause substantial dilution and pressure on the ADS trading price, and that its high debt load may require additional capital raises or refinancing to continue as a going concern.
Trinity Biotech plc submitted a Form 6-K to provide investors with a press release about its diabetes testing technology. The company announced that it is expanding the global rollout of its high-capacity column system that is used with its FDA-cleared HbA1c testing solution, which helps measure long-term blood sugar control. This expansion follows the company securing the necessary regulatory clearances to offer the system in additional markets. The full details of the announcement are contained in an attached press release, filed as Exhibit 99.1.